人胃癌组织BRSK2表达与患者临床病理学参数及预后的关系

目的 研究人胃癌组织中脑选择性蛋白激酶-2(BR-SK2)表达水平与胃癌患者临床指标及预后的关系.方法 免疫组织化学法检测121例人胃癌组织及相应癌旁正常胃黏膜组织中BRSK2蛋白的表达,分析BRSK2与临病理学参数的关系;结合患者的随访资料进一步分析BRSK2表达与胃癌患者生存的相关性(Kaplan-Meier法和Log-rank检验);最后建立Cox回归模型,评估BRSK2及各临床病理学参数与胃癌患者预后的相关性.结果 BRSK2在正常胃黏膜组织中表达水平较高,然而,其在胃癌组织中表达水平下降.62例胃癌组织中BRSK2表达降低(51.24％),明显低于癌旁正常胃黏膜组织(x2=55.22,P＜0.001).BRSK2在胃癌组织中的表达与患者肿瘤浸润深度(P ＜0.001)、肿瘤组织分化(P =0.006)、TNM分期(P ＜0.001)、淋巴结转移(P=0.001)相关,然而其与患者年龄、性别、肿瘤部位、直径、手术方式、癌胚抗原、糖类抗原19-9无相关性.生存分析表明BRSK2高表达组的胃癌患者总生存时间和无病生存时间均高于BRSK2低表达组.Cox回归分析表明BRSK2是胃癌患者的独立预后因子.结论 胃癌患者癌组织中BRSK2表达下降与肿瘤的进展及不良预后相关,表明BRSK2可以作为胃癌患者预后的分子标志物和一个潜在的治疗靶点.

Expression of BRSK2 in human gastric cancer and its relationship with clinicopathological parameters and prognosis

Objective To evaluate the correlations of BRSK2 expression with clinicopathological parameters and prognosis in gastric cancer patients.Methods BRSK2 expression in 121 gastric cancer samples and 46 adjacent normal epithelial tissues from gastric cancer patients were detected by immunohistochemistry.Results BRSK2 decreased expression in 62 of 121 cases of gastric cancer (51.24％),which was significantly higher than adjacent noncancerous epithelial tissues (x2 =55.22,P ＜ 0.001).In addition,BRSK2 decreased expression was significantly correlated with depth of invasion/T classification (P ＜ 0.001),Histological differentiation (P =0.006),TNM stage (P ＜ 0.001),and lymph node metastasis (P =0.001).Kaplan-Meier survival analysis showed that the overall survival time and disease-free survival time in patients with BRSK2-negative expression were shorter.Multivariate analysis further demonstrated that BRSK2 was an independent prognostic factor for gastric cancer patients.Conclusion The decrease of BRSK2 expression in cancer tissues of patients with gastric cancer was associated with the progression and poor prognosis of the tumor,indicating that BRSK2 could be used as a molecular marker for the prognosis of gastric cancer patients and a potential therapeutic target.